” Targeted treatments are urgently required to deal with chromophobe RCC,” said corresponding author Elizabeth P. Henske, MD, of the Division of Critical and lung Care Medicine at Brigham.
” Through our research study, weve found strong evidence that ChRCC can be therapeutically targeted by benefiting from the cells hypersensitivity to ferroptosis. This represents an essential breakthrough in our understanding as we consider treatment for patients with this uncommon illness.”
Reference: “Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic reliance and cystine import via solute carrier family 7 member 11” by Long Zhang, Charbel S. Hobeika, Damir Khabibullin, Deyang Yu, Harilaos Filippakis, Michel Alchoueiry, Yan Tang, Hilaire C. Lam, Peter Tsvetkov, George Georgiou, Candice Lamb, Everett Stone, Pere Puigserver, Carmen Priolo and Elizabeth P. Henske, 8 July 2022, Proceedings of the National Academy of Sciences.
The study was moneyed by the NIH/National Institutes of Health, the Tuttle Family, the van Hecke Family, the Christelis Family, and the Cohen/Levin Family..
There are currently no effective treatments for chromophobe renal cell cancer, an unusual type of kidney cancer.
An unique treatment for an uncommon sort of kidney cancer has been revealed.
There are presently no proven treatments for metastatic or irresectable chromophobe renal cell cancer (ChRCC), an uncommon type of kidney cancer.
Researchers offer the very first proof that ChRCC can be treated with ferroptosis in a research study headed by Brigham and Womens Hospital scientists. Ferroptosis is a sort of configured cell death that happens when extreme amounts of iron cause lipid peroxides to develop in the cell membrane.
By depriving ChRCC cells of cysteine, the team was able to induce ferroptosis, and they discovered evidence that this approach would be useful in the treatment of ChRCC.